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An antiangiogenic homoisoflavanone, cremastranone, was 
synthesized for the first time. This scalable synthesis, which 
includes selective demethylation, could be used to develop 
lead molecules to treat angiogenesis-induced eye diseases. 
Synthetic cremastranone inhibited the proliferation, 
migration and tube formation ability of human retinal 
microvascular endothelial cells, important steps in 
pathological angiogenesis. 
Retinopathy of prematurity (ROP), proliferative diabetic 
retinopathy (DR) and neovascular (“wet”) age-related macular 
degeneration (wet AMD) are three major ocular diseases, affecting 
children, adults and elderly people.1 These diseases are characterized 
by abnormal formation of blood vessels in the eye through the 
process of pathological angiogenesis. The blood vessels formed 
during pathological angiogenesis in the eye are fragile, porous and 
not completely differentiated. As a result haemorrhage, retinal 
detachment, fibrotic scarring and rapid photoreceptor degeneration 
occurs in the eye leading to vision loss. 
Nearly 2 million people are affected by wet AMD in the United 
States, while about 75% of diabetic patients show clinical symptoms 
of DR.1 Blocking pathological angiogenesis in the eyes is the current 
treatment strategy for these diseases. The current mainstay of 
therapy is the use of anti-VEGF biologics. However, these treatments 
are associated with vision damaging side effects, unfavourable cost 
to benefit ratio, and incomplete patient response.2-5 Hence there is a 
critical requirement for new therapies. Towards this goal, we are 
pursuing development of small molecules as drug leads for these 
diseases, based on natural products.  
Homoisoflavanones are a small class of naturally occurring 
oxygen heterocycles that have been isolated from many 
geographically diverse plant genera. These compounds are 
categorized into four types: 3-benzyl-4-chromanones, 3-benzylidene-
4-chromanones, 3-benzyl-3-hydroxy-4-chromanones and 
scillascillins.6 In general, these compounds are reported to show anti-
inflammatory, anti-oxidative, anti-bacterial, anti-cancer, anti-
histaminic, anti-viral, and anti-phosphodiesterase activities. 
Cremastranone (1), 5,7-dihydroxy-3-(3-hydroxy-4-methoxybenzyl)-6-
methoxychroman-4-one, is a 3-benzyl-4-chromanone that has been 
isolated from the plants Muscari armeniacum,7 Chionodoxa luciliae,8 
Scilla natalensis,9 Merwilla plumbea,10 and Cremastra appendiculata (D. 
Don)11 (1; Fig. 1). The bulb of the orchid C. appendiculata is used in 
East Asia as a traditional medicine, taken internally to treat several 
cancers, and applied externally for skin lesions. 
Fig.	  1	  The	  structures	  of	  cremastranone	  (1)	  and	  its	  congeners.
Cremastranone (1) was previously reported to possess anti-
angiogenic activity both in vitro and in vivo and was identified as a 
potent inhibitor of the proliferation of human umbilical vein 
endothelial cells (HUVECs).11 Also 1 inhibited vascular tube formation 
and new vessel growth induced by basic fibroblast growth factor. Its 
anti-angiogenic properties were further confirmed in vivo in the 
laser-induced choroidal neovascularization and oxygen induced 
retinopathy mouse models,12, 13 used for testing novel therapies for 
wet AMD and ROP, respectively. Moreover, injection of compound 1 
into the vitreous of normal adult mice showed no short-term 
cytotoxic or inflammatory effects on the retina, nor did it induce 
apoptosis of retinal cells.13 These results suggest that proliferative 
ocular vascular diseases such as ROP, DR, and AMD may be targeted 
using compound 1 or its derivatives. Other recent work has 
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suggested that 1 has potent anti-inflammatory activity in the context 
of UV-induced skin inflammation14 and allergy.15 
So far, the syntheses of 5,7-dihydroxy-6-methoxyflavones and 
5,7-dihydroxy-6-methoxyhomoisoflavanones have been reported 
(Fig. 1).16, 17 But in spite of cremastranone’s interesting biological 
activities and the synthesis of these congeners, to the best of our 
knowledge, synthesis of 1 has not yet been reported. To allow future 
profiling and development of this homoisoflavanone and its analogs, 
we sought to develop a scalable synthesis suitable for quickly 
securing multi-gram quantities. During our previous synthetic 
approach toward cremastranone, the regioisomer (SH-11052, 2) was 
generated due to the challenge of selective deprotection of methyl 
phenyl ethers.18 Herein, we describe a short and efficient synthesis of 
cremastranone (1) featuring a solution to the issue of selective 
deprotection of the methyl phenyl ether. Moreover, we show for the 
first time that synthetic cremastranone has biological properties 
consistent with the natural-source compound, in a disease relevant 
cell model. 
Our plan for the preparation of cremastranone entailed 4-
chromanone formation and deprotection of a methyl aryl ether.19 
This strategy would permit significant flexibility in the synthesis of 1 
and thereby establish a platform that leads to a variety of derivatives 
for further structure-activity relationship studies. In addition, we 
envisioned our synthesis would become very useful for the syntheses 
of similar interesting homoisoflavanones. 
Scheme	   1	   The	   initial	   synthetic	   approach	   to	   cremastranone	   (1).	   Reagents	   and	  
conditions:	   a)	   KOH,	  MeOH,	   0°C,	   54%;	   b)	   Pd/C,	   HCO2Na,	   HCO2H,	   60°C,	   79%;	   c)	  
formalin,	  NaOH,	   60°C;	   d)	   K2CO3,	   EtOH,	   47%	   for	   2	   steps;	   e)	   TMSI	   (4	   eq.),	   CHCl3,	  
50°C,	  49%;	  f)	  PCl5,	  BF3-­‐OEt2,	  DMF,	  62%;	  g)	  HBr,	  AcOH	  then	  H2,	  Pd/C.	  MeOH.	  
As shown in Scheme 1 and described previously,18 our initial 
approach toward the synthesis of cremastranone (1) began with an 
aldol condensation of the 6ʹ-hydroxy-2ʹ,3ʹ,4ʹ-trimethoxy-
acetophenone 3 with 3-benzyloxy-4-methoxybenzaldehyde 4. 
Catalytic hydrogenation of the chalcone 5 and the cyclization of the 
dihydrochalcone 6 with formaldehyde led to the desired 4-
chromanone 8 after byproducts (e.g. 7) were treated with K2CO3. 
Finally, in order to remove two methyl groups selectively, the 4-
chromanone 8 would be demethylated with a variety of reagents. 
However, the selective removal of two methyl groups under most 
conditions was not satisfactory. Among them, the demethylation 
using an excess of TMSI in CHCl3 gave the best conversion,20 but its 
product was not identical to cremastranone but rather its 
regioisomer, called SH-11052 (2). Its structure was elucidated by 2D-
NMR spectroscopies such as NOESY and HMBC.18 To overcome the 
unwanted result, the alternative 4-chromone 9 cyclized by DMF, PCl5 
was demethylated and hydrogenated.21 Similarly, the desired 
product was not afforded from 9. Surprisingly, treatment of 8 with 
BBr3 led to the other isomer demethylated on the C4ʹ position (10).22 
(Eq. 1, Scheme 2) The next trial was to remove the intermediates 
which were demethylated only on the C5 position or protected with 
a benzoyl group on the C3ʹ position. (Eq. 2 and 3, Scheme 2) 
Unfortunately, the free OH group at the C7 position could not be 
generated from any intermediates bearing 5,6,7-trimethoxy-4-
chromanone. 
Scheme	   2	   The	   study	   of	   the	   demethylation	   of	   5,6,7-­‐trimethoxy-­‐4-­‐chromanone.	  
Reagents	  and	  conditions:	  a)	  BBr3	  (or	  BCl3)	  (2.5	  eq.),	  CH2Cl2,	  –78°C,	  65%;	  b)	  TMSI,	  
CHCl3,	  reflux,	  38%;	  c)	  TMSI	  (4	  eq.),	  CHCl3,	  reflux,	  52%.	  
Finally, our key solution for an alternative route to cremastranone 
(1) was the generation of the phenol group on the C7 position prior 
to the C6 and C4ʹ positions. Thus 4ʹ-benzyloxy-6ʹ-hydroxy-2ʹ,3ʹ-
dimethoxyacetophenone 15 was chosen as the starting material 
instead of 3 (Scheme 3). As reported before, 15 was prepared from 
2ʹ,4ʹ,6ʹ-trihydroxyacetophenone with several steps.23 Aldol 
condensation of 15 with isovanillin, followed by catalytic 
hydrogenation of the chalcone 16 under H2 and Pd/C afforded the 
dihydrochalcone 17. With the dihydrochalcone 17 in hand, the 
formation of the 4-chromone was directly attempted using N,N-
dimethylformamide dimethyl acetal. However, the methylation of a 
phenol group accompanied this reaction. To overcome the side 
reaction, the dihydrochalcone 17 was carefully treated with benzyl 
bromide to afford the bis(benzyl ether) 18 which was converted to 
the corresponding 4-chromone 19. To this end, catalytic 
hydrogenation of 19 led to the desired 4-chromanone 20. Finally, 
methyl groups were removed by 2 equivalents of TMSI to give 
cremastranone (1). Thus the antiangiogenic homoisoflavanone 
cremastranone is available in 6 steps and 26.8% overall yield from the 
acetophenone 15.  Although our synthetic cremastranone is a 
racemate, its chemical shifts in 1H- and 13C-NMR spectra match those 
of the reported natural product (Supplementary Table 1).7 To date, 
the configuration at C3 for natural-source compound 1 has not been 
reported. Further experiments are necessary to determine the 
absolute configuration of the C3 position in compound 1. 
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Scheme	   3	   First	   synthesis	  of	   (±)-­‐cremastranone	   (1).	  Reagents	  and	  conditions:	  a)	  
isovanillin,	   KOH,	   EtOH,	   rt,	   53%;	   b)	   H2,	   Pd/C,	   MeOH,	   94%;	   c)	   K2CO3,	   benzyl	  
bromide,	  acetone,	  reflux,	  89%;	  d)	  (CH3)2NCH(OCH3)2,	  toluene,	  reflux,	  80%;	  e)	  H2,	  
Pd/C,	  MeOH,	  87%;	  f)	  TMSI	  (2	  eq.),	  CHCl3,	  60°C,	  87%.	  
Previously, cremastranone isolated from C. appendiculata was 
tested for its anti-proliferative activity against an endothelial cell 
model, human umbilical vein endothelial cells (HUVECs), and the 50% 
growth inhibitory concentration (GI50) value was reported to be 1.5 
µM.11 Hence, we tested the anti-proliferative activity of synthetic 
cremastranone 1 on HUVECs in an alamarBlue fluorescence cell 
proliferation assay and the GI50 was observed to be 377 nM. The 
slightly higher potency of synthetic 1 might be attributed to a 
difference in the proliferation assays used or compound purity. 
Further, we tested the anti-proliferative activity of 1 against a more 
ocular disease relevant endothelial cell model, human retinal 
microvascular endothelial cells (HRECs). We observed clear dose 
dependent inhibition of HREC proliferation by 1 in complete medium 
with a GI50 of 217 nM (Fig. 2a). In addition we also tested the 
proliferation of HRECs activated by vascular endothelial growth factor, 
a potent inducer of angiogenesis, in the presence of 1 and found the 
GI50 to be comparable (276 nM). Previously we reported a GI50 of 43 
µM for regioisomer SH-11052 (2),18 which differed only in the 
positions of hydroxyl and methoxy groups at C6 and C7 as compared 
to 1. The importance of positions of the groups on the ‘A’ ring 
suggest that a structure-activity relationship can be established. 
We then measured the endothelial cell specificity of 1 by 
measuring its effects on the proliferation of non-endothelial ocular 
cell lines, Y79 (retinoblastoma cell line), 92-1 (uveal melanoma cell 
line) and ARPE-19 (retinal pigmented epithelial cells). The anti-
proliferative potency of 1 on these non-endothelial cell lines was 
significantly lower than that on endothelial cells with GI50 values of 
9.8 µM, 47 µM, and >250 µM on Y79, 92-1, and ARPE-19 cells 
respectively, indicating that compound 1 has highly specific 
antiproliferative activity toward endothelial cells. We further 
confirmed the inhibition of HREC proliferation by 1 in a secondary 
assay by monitoring the incorporation of thymidine analogue 5-
ethynyl-2ʹ-deoxyuridine (EdU) into DNA of endothelial cells in the 
presence of different concentrations of 1. In this EdU incorporation 
assay, compound 1 inhibited the DNA synthesis of HRECs in a dose 
dependent manner (Fig. 2b, e). 
After establishing the inhibition of HREC proliferation by 1, we 
tested its anti-angiogenic activity in vitro. We tested the ability of 
HRECs to form tubes in vitro in a Matrigel tube formation assay, which 
recapitulates in vitro major events of physiological angiogenesis. 
Cremastranone 1 prevented the formation of closed tube structures 
in a dose dependent manner as measured by both tube length (Fig. 
2c, f) and number of polygons formed (data not shown). This is 
consistent with previous findings with the natural-source 
cremastranone in HUVECs.11 Migration is also an important step in 
the angiogenesis process, wherein endothelial cells move from pre-
existing capillaries to the site of blood vessel formation. We 
measured this ability of HRECs to migrate using the standard scratch-
wound assay, in which HRECs were allowed to grow to confluency, 
then a scratch was introduced and movement of endothelial cells 
into the scratched area from the surrounding population was 
measured in the presence of various concentrations of 1 (Fig. 2d). The 
migration of HRECs was inhibited by 1 in a dose dependent manner.  
In summary, a novel scalable strategy to synthesize the 
biologically active homoisoflavanone cremastranone was developed, 
and the resulting compound showed potent activity in cell models. 
Together, these results confirm the anti-angiogenic activity of 
synthetic cremastranone 1 in a disease-relevant cell type, and pave 
the way for development of analogues with higher potency and 
better pharmacological properties to treat blinding ocular diseases 
caused by pathological angiogenesis. 
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Fig.	  2	  Synthetic	  cremastranone	  (1)	  blocks	  in	  vitro	  angiogenesis	  of	  human	  retinal	  microvascular	  endothelial	  cells	  (HRECs)	  in	  a	  dose-­‐dependent	  manner.	  (a)	  The	  effect	  of	  1	  on	  
proliferation	  of	  HRECs	  was	  tested	  using	  an	  alamarBlue	  fluorescence	  assay.	  (b,	  e)	  In	  an	  EdU	  incorporation	  assay,	  1	  blocked	  DNA	  synthesis	  as	  evidenced	  by	  a	  decrease	  in	  	  
incorporation	   of	   EdU	   (pink)	   into	   the	   nuclei	   of	   HRECs	   (nuclei,	   blue).	   (c,	   f)	   Tube	   formation	   by	   HRECs	   on	  Matrigel	  was	   blocked	   by	  1;	   the	   extent	   of	   tube	   formation	  was	  
measured	  as	  tubule	  length.	  (d)	  Migration	  of	  HRECs	  in	  a	  scratch-­‐wound	  assay	  was	  inhibited	  by	  1.	  Original	  magnifications:	  40x.	  The	  data	  points	  in	  all	  graphs	  indicate	  mean	  ±	  
SEM;	  **	  represents	  P	  <	  0.01;	  ***	  represents	  P	  <	  0.001	  (ANOVA	  with	  Dunnett’s	  post	  hoc	  tests).	  Each	  of	  the	  panels	  is	  representative	  of	  three	  independent	  experiments.	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Synthetic Methodology 
All starting materials and reagents were obtained commercially and were used without further 
puriﬁcation. Tetrahydrofuran was distilled from sodium benzophenone ketyl. Dichloromethane and 
acetonitrile were freshly distilled from calcium hydride. All solvents used for routine product isolation 
and chromatography were of reagent grade and glass distilled. Reaction glassware was dried at 100 °C 
before use, and air- and moisture-sensitive reactions were performed under argon. Flash column 
chromatography was performed using silica gel 60 (230−400 mesh, Merck) with the indicated solvents. 
Thin-layer chromatography was performed using 0.25 mm silica gel plates (Merck). Mass spectra were 
obtained using a Waters Auto Purification instrument. 1H and 13C spectra were recorded on either a 
Bruker 600MHz spectrometer or a Bruker 400MHz spectrometer as solutions in deuteriochloroform 
(CDCl3) or methanol-d4 (CD3OD). 1H NMR data are reported in the order of chemical shift, multiplicity 
(s, singlet; d, doublet; t, triplet; m, multiplet and/or multiple resonances), number of protons, and coupling 
constant (J) in Hertz (Hz). 
 
5,6-dihydroxy-3-(3ʹ-hydroxy-4ʹ-methoxybenzyl)-7-methoxychroman-4-one (2) 
SH-11052 (2) and intermediates 5, 6, 7, and 8 were synthesized as previously described.1 
 S2 
3-(3ʹ-hydroxy-4ʹ-methoxybenzyl)-5,6,7-trimethoxy-4H-chromen-4-one (9) 
A solution of PCl5 (180 mg, 0.86 mmol) in DMF (2.5 mL) was stirred at 20 °C for 20 min. To the 
reaction mixture was added BF3-Et2O (0.22 mL, 1.73 mmol) and the dihydrochalcone 1-(6-hydroxy-2,3,4-
trimethoxyphenyl)-3-(3ʹ-hydroxy-4ʹ-methoxyphenyl)propan-1-one (6) (200 mg, 0.55 mmol) at 20 °C, 
then the mixture was stirred for 4 h followed by the addition of 1N HCl (2 mL) and dilution with ethyl 
acetate. The organic layer was washed with water and brine, dried over MgSO4, and concentrated in 
vacuo. The residue was purified by silica gel column chromatography (ethyl acetate / n-hexane = 1 : 4) to 
afford the chromone (9) (128 mg, 62%). 1H-NMR (400 MHz, CDCl3) δ 7.34 (s, 1H), 6.83-6.79 (m, 2H), 
6.74-6.73 (m, 1H), 6.59 (s, 1H), 5.49 (s, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 3.86 (s, 3H), 3.67 (s, 2H) ; 13C-
NMR (100 MHz, CDCl3) δ 175.9, 157.5, 154.7, 152.6, 151.0, 146.5, 144.1, 140.2, 130.6, 125.2, 121.6, 
114.3, 112.9, 111.7, 95.9, 62.0, 61.4, 56.2, 55.9, 31.1.; HRMS (ESI): mass calcd for C20H20O7 [M + H]+, 
373.1287; found, 373.1280. 
 
3-(3ʹ,4ʹ-dihydroxybenzyl)-5-hydroxy-6,7-dimethoxychroman-4-one (10) 
i) For synthesis from compound (8), 
To a CH2Cl2 (3 mL) solution of the 3-(3-hydroxy-4-methoxybenzyl)-5,6,7-trimethoxychroman-4-one (8) 
(42 mg, 0.11 mmol), boron tribromide (1.0 M solution of CH2Cl2, 280 µL, 0.28 mmol) was added at –78 
°C. After stirring for 1 h, the reaction mixture was heated to ambient temperature, quenched with 
methanol, and stirred for 30 min. The organic phase was washed with water and brine, dried over MgSO4 
and concentrated under reduced pressure. The residue was purified by flash column chromatography 
(ethyl acetate / n- hexane = 1 : 2) to afford demethylated compound (10) (25 mg, 65%); 1H-NMR (600 
MHz, CD3OD) δ 6.71 (d, 1H, J = 6.8 Hz), 6.67 (d, 1H, J = 2.4 Hz), 6.55 (dd, 1H, J = 7.8 and 1.8 Hz), 
6.14 (s, 1H), 4.29 (dd, 1H, J = 11.4 and 4.2 Hz), 4.13 (dd, 1H, J =11.4 and 7.8 Hz), 3.87 (s, 3H), 3.73 (s, 
3H), 3.03 (dd, 1H, J = 13.8 and 4.8 Hz), 2.82 (m, 1H), 2.59 (dd, 1H, J = 14 and 10 Hz); 13C-NMR (150 
MHz, CD3OD) δ 200.6, 162.3, 160.6, 156.2, 146.5, 145.2, 131.3, 130.8, 121.5, 117.1, 116.5, 103.6, 92.5, 
70.5, 61.1, 56.8, 33.1. 
 
 S3 
ii) For synthesis from 5,6,7-methoxy-4-chromanone (10-1), 
  
To a solution of 5,6,7-methoxy-4-chromanone (10-1) (108 mg, 0.42 mmol) in benzene (5 mL) was 
added 3ʹ,4ʹ-bis(benzyloxy)benzaldehyde (102 mg, 0.45 mmol) and PTSA (9 mg, 0.04 mmol) at 0 °C. The 
reaction mixture was refluxed for 12 h. After cooling to ambient temperature, the reaction mixture was 
concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl 
acetate / n-hexane = 1 : 2) to afford (E)-3-(3ʹ,4ʹ-bis(benzyloxy)benzylidene)-5,6,7-trimethoxychroman-4-
one (10-2) (117 mg, 51%). And then to an anhydrous MeOH solution of the benzylidene (10-2) (78 mg, 
0.15 mmol) and 10% Pd/C (8 mg) was placed under an atmosphere of hydrogen. After stirring for 1 h, the 
reaction mixture was diluted with ethyl acetate, filtered through a Celite pad and concentrated under 
reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate / 
n-hexane = 1 : 5) to afford the homoisoflavanone (10-3) (42 mg, 77%). 1H-NMR (600 MHz, CDCl3) δ 
6.78 (d, 1H, J = 4.8 Hz), 6.76 (s, 1H), 6.57 (dd, 1H, J =7.8 and 2.4 Hz), 6.22 (s, 1H), 4.24 (dd, 1H, J = 11 
and 4.2 Hz), 4.09 (dd, 1H, J = 12 and 7.2 Hz), 3.90 (s, 3H), 3.84 (s, 3H), 3.77 (s, 3H), 3.05 (dd, 1H, J = 
7.8 and 4.8 Hz), 2.68 (m, 1H), 2.58 (dd, 1H, J = 14 and 10 Hz); 13C-NMR (150 MHz, CDCl3) δ 192.7, 
160.0, 159.7, 154.3, 144.1, 142.8, 137.3, 130.5, 121.3, 115.9, 115.3, 108.3, 96.1, 69.0, 61.6, 61.3, 56.1, 
48.5, 32.5 ; HRMS (ESI): mass calcd for C19H20O7 [M + H]+, 361.1287; found, 361.1275. To a CH2Cl2 (3 
mL) solution of the 3-(3ʹ,4ʹ-dihydroxybenzyl)-5,6,7-trimethoxychroman-4-one (10-3) (38 mg, 0.1 mmol) 
boron trichloride (1.0 M solution of CH2Cl2, 500 µL, 0.5 mmol) was added at –78 °C. After stirring for 1 
h, the reaction mixture was heated to ambient temperature, quenched with methanol, and stirred for 30 
min. The organic phase was washed with water and brine, dried over MgSO4 and concentrated under 
reduced pressure. The residue was purified by flash column chromatography (ethyl acetate / n-hexane = 
1 : 2) to afford demethylated compound (10) (13 mg, 38%). 1H-NMR (600 MHz, CD3OD) δ 6.71 (d, 1H, 
J = 6.8 Hz), 6.67 (d, 1H, J = 2.4 Hz), 6.55 (dd, 1H, J = 7.8 and 1.8 Hz), 6.14 (s, 1H), 4.29 (dd, 1H, J = 
11.4 and 4.2 Hz), 4.13 (dd, 1H, J =11.4 and 7.8 Hz), 3.87 (s, 3H), 3.73 (s, 3H), 3.03 (dd, 1H, J = 13.8 and 
4.8 Hz), 2.82 (m, 1H), 2.59 (dd, 1H, J = 14.4 and 10.2 Hz); 13C-NMR (150 MHz, CD3OD) δ 200.6, 162.3, 
160.6, 156.2, 146.5, 145.2, 131.3, 130.8, 121.5, 117.1, 116.5, 103.6, 92.5, 70.5, 61.1, 56.8, 33.1; HRMS 
(ESI): mass calcd for C18H18O7 [M + H]+, 347.1131; found, 347.1122 
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5-hydroxy-3-(3ʹ-hydroxy-4ʹ-methoxybenzyl)-6,7-dimethoxychroman-4-one (11) 
To a solution of 3-(3ʹ-hydroxy-4ʹ-methoxybenzyl)-5,6,7-trimethoxychroman-4-one (8) (70 mg, 0.187 
mmol) in CHCl3 (2 mL) was added TMSI (53 µL, 0.374 mmol) at 0 °C and the reaction mixture was 
heated at 60 °C for 1 h. The mixture was concentrated in vacuo. The residue was purified by flash column 
chromatography on silica gel (ethyl acetate / n-hexane = 1 : 2) to afford compound 11 (49 mg, 73%). 1H-
NMR (600 MHz, CD3OD) δ 6.85 (d, 1H, J = 7.8 Hz), 6.71 (d, 1H, J = 1.8 Hz), 6.66 (dd, 1H, J = 8.4 and 
2.4 Hz), 6.14 (s, 1H), 4.29 (dd, 1H, J = 11.4 and 4.2 Hz), 4.12 (dd, 1H, J = 11.4 and 7.2 Hz), 3.86 (s, 3H), 
3.83 (s, 3H), 3.73 (s, 3H), 3.09 (dd, 1H, J = 13.8 and 4.2 Hz), 2.87-2.82 (m, 1H), 2.64 (dd, 1H, J = 14.4 
and 10.2 Hz); 13C-NMR (150 MHz, CD3OD) δ 200.5, 162.4, 160.7, 156.2, 148.0, 147.8, 132.3, 131.4, 
121.4, 117.1, 113.0, 103.7, 92.6, 70.6, 61.2, 56.8, 56.5, 48.2, 33.1; HRMS (ESI): mass calcd for C19H20O7 
[M + H]+, 361.1287; found, 361.1277. 
 
2ʹ-methoxy-5ʹ-((5,6,7-trimethoxy-4-oxochroman-3-yl)methyl)phenyl benzoate (13) 
To a solution of 3-(3ʹ-hydroxy-4ʹ-methoxybenzyl)-5,6,7-trimethoxychroman-4-one (8) (149 mg, 0.39 
mmol) in  CH2Cl2 (2.5 mL) was added Et3N (0.11 mL, 0.78 mmol), DMAP (10 mg, 0.08 mmol), and 
benzoyl chloride (0.05 mL, 0.47 mmol) at 0 °C and the reaction mixture was stirred at ambient 
temperature for 2 h. The reaction mixture was diluted with ethyl acetate and the organic phase was 
washed with water and brine, dried over MgSO4 and concentrated under reduced pressure. The residue 
was purified by flash column chromatography on silica gel (ethyl acetate / n-hexane = 1 : 2) to afford the 
benzoate compound (13) (182 mg, 80%). 1H-NMR (400 MHz, CDCl3) δ 8.18-8.16 (m, 2H), 7.60-7.56 (m, 
1H), 7.48-7.44 (m, 2H), 7.06 (d, 1H, J = 7.8 Hz), 6.86 (d, 1H, J = 1.9 Hz), 6.83 (dd, 1H, J = 8.3 and 1.9 
Hz), 6.23 (s, 1H), 4.31 (dd, 1H, J = 11 and 3.9Hz), 4.13 (dd, 1H, J = 11 and 7.8 Hz), 3.91 (s, 3H), 3.84 (s, 
3H), 3.78 (s, 3H), 3.77 (s, 3H), 3.26 (dd, 1H, J = 14 and 3.9 Hz), 2.81 (m, 1H), 2.70 (dd, 1H, J = 14 and 
11 Hz); 13C-NMR (100 MHz, CDCl3) δ 190.9, 164.6, 159.6, 159.2, 154.3, 151.2, 138.5, 137.4, 133.3, 
130.1, 129.9, 129.2, 128.3, 128.2, 122.7, 121.2, 113.1, 108.5, 95.9, 68.9, 61.5, 61.1, 56.0, 55.8, 48.2, 32.6. 
 
5ʹ-((5,6-dihydroxy-7-methoxy-4-oxochroman-3-yl)methyl)-2ʹ-methoxyphenyl benzoate (14) 
To a solution of benzoate (13) (65 mg, 0.136 mmol) in CHCl3 (1 mL) was added TMSI  (77 µL, 0.54 
mmol) at 0 °C and the reaction mixture was heated at 60 °C for 1 h. The mixture was concentrated in 
vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate / n-hexane = 
2 : 3) to afford the compound 14 (32 mg, 52%). 1H-NMR (400 MHz, CDCl3) δ 8.20 (m, 2H), 7.63 (m, 
1H), 7.51 (m, 2H), 7.09 (d, 1H, J = 7.8 Hz), 6.87 (d, 1H, J = 2.0 Hz), 6.85 (dd, 1H, J = 7.8 and  2.0 Hz), 
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6.06 (s, 1H), 4.32 (dd, 1H, J = 11 and 3.9 Hz), 4.16 (dd, 1H, J = 11 and 7.3 Hz), 3.90 (s, 3H), 3.82 (s, 3H), 
3.26 (dd, 1H, J = 14 and 3.9 Hz), 2.89-2.87 (m, 1H), 2.78 (dd, 1H, J =14 and 11 Hz); 13C-NMR (100 
MHz, CDCl3) δ 198.4, 164.7, 155.9, 154.7, 151.4, 148.1, 138.8, 136.8, 133.4, 130.2, 129.3, 128.5, 127.3, 
123.0, 121.3, 113.2, 102.4, 91.0, 69.2, 56.3, 55.9, 46.8, 32.7, 30.9. 
 
(E)-1-(4-(benzyloxy)-6-hydroxy-2,3-dimethoxyphenyl)-3-(3ʹ-hydroxy-4ʹ-methoxyphenyl)prop-2-en-
1-one (16) 
To a solution of 4ʹ-benzyloxy-6ʹ-hydroxy-2ʹ,3ʹ-dimethoxyacetophenone (15) (104 mg, 0.34 mmol) in 
EtOH (6 mL) was added KOH (95 mg, 1.7 mmol) and isovanillin (62 mg, 0.41 mmol) at rt. The reaction 
mixture was stirred for 48 h at rt. The mixture was concentrated in vacuo. The residue was washed with 2 
N HCl solution and brine. Drying over MgSO4 and removal of the solvent followed by column 
chromatography on silica gel using (ethyl acetate / n-hexane = 1 : 2) gave the chalcone (16) (67 mg, 53%) 
as a yellow solid. 1H-NMR (600 MHz, CDCl3) δ 13.68 (s, 1H), 7.81 (d, 1H, J = 15.6 Hz), 7.75 (d, 1H, J = 
15.6 Hz), 7.42 (d, 2H, J = 6.6 Hz), 7.38 (t, 2H, J =7.8 Hz), 7.33 (t, 1H, J = 7.2 Hz), 7.26 (d, 1H, J = 2.4 
Hz), 7.11 (dd, 1H, J = 8.4 and 2.4 Hz), 6.85(d, 1H, J =8.4 Hz), 6.32 (s, 1H), 5.12 (s, 2H), 3.92 (s, 3H), 
3.91 (s, 3H), 3.83 (s, 3H); 13C-NMR (150 MHz, CDCl3) δ 192.8, 162.4, 159.1, 155.1, 148.7, 145.9, 143.5, 
135.8, 135.5, 129.0, 128.7, 128.2, 127.3, 124.6, 122.8, 113.0, 110.5, 109.0, 97.7, 70.6, 61.9, 61.3, 56.0 ; 
HRMS (ESI): mass calcd for C25H24O7 [M + H]+, 437.1600; found, 437.1620. 
 
1-(4,6-dihydroxy-2,3-dimethoxyphenyl)-3-(3ʹ-hydroxy-4ʹ-methoxyphenyl)propan-1-one (17) 
A solution of the chalcone (16) (40 mg, 0.11 mmol) and 10% Pd/C (20 mg) in anhydrous MeOH was 
placed under an atmosphere of hydrogen. After stirring for 1 h, the reaction mixture was diluted with 
ethyl acetate, filtered through a Celite pad and concentrated under reduced pressure. The residue was 
purified by flash column chromatography on silica gel (ethyl acetate : n-hexane = 1 : 2) to afford the 
dihydrochalcone (17) (30 mg, 94%). 1H-NMR (600 MHz, CDCl3) δ 13.23 (s, 1H), 6.81 (d, 1H, J = 2.4 
Hz), 6.77 (d, 1H, J = 7.8 Hz), 6.71 (dd, 1H, J = 8.4 and 2.4 Hz), 6.27 (s, 1H), 5.60 (s, 1H), 3.90 (s, 3H), 
3.85 (s, 3H), 3.80 (s, 3H), 3.3 (t, 2H, J = 7.8Hz), 2.92 (t, 2H, J = 7.8 Hz); 13C-NMR (150 MHz, CDCl3) δ 
207.6, 161.8, 156.2, 154.4, 145.5, 144.8, 134.7, 132.7, 119.8, 114.56, 110.7, 108.5, 99.1, 60.9, 60.6, 56.0, 
44.9, 29.8 ; HRMS (ESI): mass calcd for C18H20O7 [M + H]+, 349.1287; found, 349.1272. 
 
 S6 
3-(3ʹ-(benzyloxy)-4ʹ-methoxyphenyl)-1-(4-(benzyloxy)-6-hydroxy-2,3 dimethoxyphenyl)propan-1-
one (18) 
To an acetone (5 mL) solution of the dihydrochalcone 17 (250 mg, 0.72 mmol) were added benzyl 
bromide (270 mg, 1.6 mmol) and K2CO3 (300 mg, 2.2 mmol). After refluxing for 3 h, the reaction 
mixture was diluted with ethyl acetate and the organic phase was washed with water and brine, dried over 
MgSO4 and concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (ethyl acetate / n-hexane = 1 : 2) to afford the dibenzylated compound (18) 
(340 mg, 89%). 1H-NMR (600 MHz, CDCl3) δ 13.29 (s, 1H), 7.42 (m, 4H), 7.38 (t, 2H, J = 7.2 Hz), 7.33 
(t, 3H, J = 7.2 Hz), 7.26 (t, 1H, J = 7.2 Hz), 6.83(d, 1H, J = 9.0 Hz), 6.78 (dd, 2H, J = 6.0 and 1.8 Hz), 
6.27 (s, 1H), 5.12 (s, 2H), 5.10 (s, 2H), 3.87 (s, 3H), 3.84 (s, 3H), 3.76 (s, 3H), 3.25 (t, 2H, J = 7.2 Hz), 
2.89 (t, 2H, J =7.8 Hz); 13C-NMR (150 MHz, CDCl3) δ 204.8, 159.0, 155.2, 148.0, 137.2, 135.7, 134.9, 
134.0, 128.7, 128.5, 128.2, 127.7, 127.3, 127.2, 120.9, 114.7, 111.9, 108.4, 97.3, 71.0, 70.5, 61.1, 61.0, 
56.1, 45.0, 29.9 ; HRMS (ESI): mass calcd for C32H32O7 [M + H]+, 529.2226; found, 529.2207. 
 
7-(benzyloxy)-3-(3ʹ-(benzyloxy)-4ʹ-methoxybenzyl)-5,6-dimethoxy-4H-chromen-4-one (19) 
To a solution of the dibenzylated dihydrochalcone (18) (93 mg, 0.2 mmol) in toluene (5 mL) was 
added N,N-dimethylformamide dimethyl acetal (43 mg, 0.36 mmol). After refluxing for 6 h, the reaction 
mixture was cooled and concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (ethyl acetate / n-hexane = 1 : 2) to afford the 4-chromone (19) (76 mg, 
80%). 1H-NMR (600 MHz, CDCl3) δ 7.44 (d, 2H, J = 8.4 Hz), 7.40 (t, 4H, J = 7.2 Hz), 7.34 (t, 1H, J = 
6.0 Hz), 7.29 (t, 2H, J = 7.2 Hz), 7.22 (m, 2H), 6.80 (s, 2H), 6.77 (s, 1H), 6.63 (s, 1H), 5.16 (s, 2H), 5.09 
(s, 2H), 3.95 (s, 3H), 3.89 (s, 3H), 3.93 (s, 3H), 3.62 (s, 2H); 13C-NMR (150 MHz, CDCl3) δ 175.9, 156.6, 
154.5, 152.8, 151.0, 148.3, 148.0, 140.6, 137.1, 135.6, 131.2, 128.7, 128.4, 128.3, 127.7, 127.4, 127.2, 
125.0, 121.8, 115.3, 113.1, 112.0, 97.4, 71.0, 70.8, 62.1, 61.5, 56.1, 30.8 ; HRMS (ESI): mass calcd for 
C33H30O7 [M + H]+, 539.2070; found, 539.2049. 
 
7-hydroxy-3-(3ʹ-hydroxy-4ʹ-methoxybenzyl)-5,6-dimethoxychroman-4-one (20) 
A solution of the chromone (19) (35 mg, 0.07 mmol) and 10% Pd/C (10 mg) in MeOH was placed 
under an atmosphere of hydrogen. After stirring for 1 h, the reaction mixture was diluted with ethyl 
acetate, filtered through a Celite pad and concentrated under reduced pressure. The residue was purified 
by flash column chromatography on silica gel (ethyl acetate : n-hexane = 1 : 1) to afford the 4-
chromanone (20) (22 mg, 87%). 1H-NMR (600 MHz, CD3OD) δ 6.82 (d, 1H, J = 14.4 Hz), 6.67 (d, 1H,  
 S7 
J = 1.8 Hz), 6.63 (dd, 1H, J = 8.4 and 2.4 Hz), 6.16 (s, 1H), 4.21 (dd, 1H, J = 11.4 and 4.2 Hz), 4.04 (dd, 
1H, J = 11.4 and 7.2 Hz), 3.82 (s, 3H), 3.79 (s, 3H), 3.75 (s, 3H), 3.00 (dd, 1H, J = 13.2 and 4.2 Hz), 2.66 
(m, 1H), 2.58 (dd, 1H, J = 13.8 and 10.8Hz); 13C-NMR (150 MHz, CD3OD) δ 192.4, 160.0, 158.5, 154.4, 
146.3, 146.2, 136.4, 131.2, 119.9, 115.6, 111.5, 107.3, 99.1, 68.6, 60.4, 60.1, 55.0, 48.2, 32.0 ; HRMS 
(ESI): mass calcd for C19H20O7 [M + H]+, 361.1287; found, 361.1270. 
 
Cremastranone (1) 
To a solution of 7-hydroxy-3-(3-hydroxy-4-methoxybenzyl)-5,6-dimethoxychroman-4-one (20) (113 
mg, 0.315 mmol) in CHCl3 (3 mL) was added TMSI (89 µL, 0.63 mmol) at 0 °C and the reaction mixture 
was stirred at RT for 30 min. The mixture was concentrated in vacuo. The residue was purified by flash 
column chromatography on silica gel (ethyl acetate / n-hexane = 1 : 1) to afford cremastranone (1) (95 mg, 
87%). 1H-NMR (600 MHz, CD3OD) δ 6.85 (d, 1H, J = 8.4 Hz), 6.70 (d, 1H, J = 1.8 Hz), 6.68 (dd, 1H, J 
= 8.4 and 2.4 Hz), 5.91 (s, 1H), 4.23 (dd, 1H, J = 11.4 and 4.2 Hz), 4.06 (dd, 1H, J = 11.4 and 7.2 Hz), 
3.82 (s, 3H), 3.77 (s, 3H), 3.08 (dd, 1H, J = 13.8 and 4.8 Hz), 2.82 (m, 1H), 2.63 (dd, 1H, J = 13.8 and 
4.2Hz); 13C-NMR (150 MHz, CD3OD) δ 200.1, 160.6, 160.1, 156.8, 147.8, 147.6, 132.2, 130.4, 121.3, 
117.0, 112.9, 102.9, 95.7, 70.3, 60.9, 56.4, 47.9, 33.1; HRMS (ESI): mass calcd for C18H18O7 [M + H]+, 
347.1131; found, 347.1118. Purity >95% by LC-MS. 
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ESI Table 1. Chemical shifts in 1H- and 13C-NMR for selected compounds. 
 
Reported natural 
product (1)2 
New synthetic 
compound (1) 
Synthetic 
compound (2) 
by TMSI 
Synthetic  
compound (10) 
by BBr3 
1H 13C 1H 13C 1H 13C 1H 13C 
2 4.06, 4.23 70.3 
4.07, 
4.23 70.3 
4.11, 
4.25 70.6 
4.13, 
4.29 70.6 
4 2.81 200 2.82 200.1 2.87 200.6 2.85 200.6 
4a - 103  102.9  103.5 - 103.7 
5 12.22 156.8  156.8  157.5 - 156.3 
6 3.82a 129.2 3.82a 130.4 3.87a 128.7 3.87  
7 9.87 160.9  160.7  149.3 - 162.4 
8 5.91 95.8 5.91 95.8 6.14 97 6.15 92.6 
8a  160.1  160.1  148.7 - 160.7 
9 2.62, 3.06 33.1 
2.63, 
3.08 33.1 
2.69, 
3.12 33.2 
2.62, 
3.06 33.2 
1ʹ - 132.3  132.3  132.4 - 130.8 
2ʹ 6.71 117 6.71 117 6.73 117.1 6.67 117.2 
3ʹ 8.75 147.8  147.8  147.9 - 146.6 
4ʹ 3.77a 147.8 3.77a 147.7 3.83a 147.7 3.74 145.3 
5ʹ 6.85 112.9 6.85 112.9 6.8 112.5 6.71 116.6 
6ʹ 6.66 121.3 6.66 121.3 6.67 121.4 6.56 121.6 
6-OCH3 - 61  60.9  61.6 - 61.2 
7-OCH3 -      -  
3ʹ-OCH3 -      -  
4ʹ-OCH3 - 56.4  56.4  56.5 - 56.8 
a : revised assignment by HMBC 
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 S11 
1H-NMR (600MHz, CD3OD) of Cremastranone (1) 
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13C-NMR (150MHz, CD3OD) of Cremastranone (1) 
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1H-NMR (600MHz, CD3OD) of SH-11052 (2) 
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1H-NMR (600MHz, CD3OD) of compound 10 
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Biological Methods 
Cell proliferation assay 
The proliferation of cells was monitored by an alamarBlue based fluorescence assay as described 
previously.1 Briefly, 2500 cells in 100 µL growth medium were incubated in 96-well clear bottom black 
plates at 37 °C, 5% CO2 for 24 hours followed by 44 hours incubation with different concentrations of 1 
in DMSO (range: 0.5 nM to 500 µM; final DMSO concentration 1%). Cells used were: Human umbilical 
vein endothelial cells (HUVECs; Lonza) and human retinal endothelial cells (HRECs; Cell Systems) in 
EGM-2 medium (Lonza); Y-79 retinoblastoma cells3 (a kind gift of Dr. Brenda L. Gallie, Ontario Cancer 
Institute) in previously described medium;4 92-1 uveal melanoma cells5 (a kind gift of Dr. Martine Jager, 
University of Leiden) in RPMI-1640, 10% FBS, penicillin/streptomycin; and ARPE-19 human retinal 
pigment epithelial cells6 (a kind gift of Dr. Michael Boulton, Indiana University) in Ham’s F10, 10% FBS, 
penicillin/streptomycin. For VEGF-induced proliferation, HRECs plated as above were starved with 
EBM-2 medium (Lonza) overnight, then incubated for 44 hours with different concentrations of 1 plus 50 
ng/mL human VEGF-165 (BioLegend) in EBM-2. At the end of each incubation, 11.1 µL of alamarBlue 
reagent (AbDSerotec) was added and 4 hours after, fluorescent readings were taken on a Synergy H1 
plate reader (Biotek) with excitation and emission wavelengths of 560 nm and 590 nm respectively. Data 
were analysed and dose response curves generated using GraphPad Prism software (v. 6.0). 
 
EdU incorporation assay 
The assay was carried out as described before.1 HRECs (25,000) were seeded onto coverslips coated 
with attachment factor and grown for 24 hours before starving in serum-free EBM-2 medium. After 
starvation for 12 hours, the cells were incubated with 10 µM 5-ethynyl-2ʹ-deoxyuridine (EdU) in the 
presence of various concentrations of 1 for 8 hours. Then the cells were processed according to the 
manufacturer’s instructions for the click-iT EdU assay kit (Life Technologies). The images were taken 
using an EVOS microscope (AMG) and data were analysed using ImageJ. 
 
In vitro angiogenesis assay 
Matrigel based tube formation assay was performed to monitor the tube-formation ability of HRECs 
in the presence of 1 as described previously.1 Briefly, 7500 cells in 100 µL EGM-2 medium were 
incubated in the presence or absence of 1 in 96-well clear plates coated with 75 µL of Matrigel basement 
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membrane. After 8 hours, images were recorded using the EVOS microscope. Number of polygons was 
manually counted, and the tube length was measured using Angiogenesis Analyser macros7 in ImageJ. 
 
In vitro scratch assay 
HRECs (105) were seeded in each well of a 6-well plate coated with attachment factor (Cell Systems). 
The cells were incubated in EGM-2 medium until confluent (~24 hours). The cells were then starved for 
12 hours in serum free EBM-2 medium. After starvation, a straight scratch was introduced in the well by 
a sterile, fine 10 µL micropipette tip, and the well was rinsed twice using EBM-2 medium to remove 
unbound cells and debris. Then cells were incubated in EGM-2 medium in the presence of the indicated 
concentrations of 1 at 37 °C and 5% CO2. After 8 hours, images were taken using the EVOS microscope 
and the number of migrated cells into the scratched area was counted. 
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